TGFB1 and carcinoma: In vivo, treatment with the soluble TGF-β type II receptor-murine Fc:IgG2A fusion protein (Fc:TβRII), a specific inhibitor of TGF-β1 and -β3, reduces intratumoral collagen density and influences the collagen network architecture in xenograft human KAT-4 cell-derived carcinoma [18].